Description
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Share Price
Recent Amphion Innovations news
- 08/06/2010 Amphion Innovations to progress IP licensing with renewed confidence
- 30/03/2010 Amphion Innovations CEO buys 65,000 more shares
- 16/03/2010 Amphion Innovations continues progress in 2009 as IP Licensing business drives growth
- 15/03/2010 Amphion Innovations partner Kromek raises £12.3 million to fund expansion
- 03/03/2010 Amphion Innovations partner WellGen's theaflavin tea extract gets positive review
Presentations & Company Media
01/05/2009 Amphion Annual Report and Accounts 2008 (Presentation)
01/01/2009 Amphion Brochure (Presentation)
Related Research & Media
02/07/2009 Reuters Article "Amphion CEO Sees Key Unit Beating FY Target" 2 July 2009 (Presentation)
26/10/2008 Financial Times Article "Lessons Learnt from the Halls of Academia" 26 Oct 08 (Presentation)
08/02/2008 Investors Chronicle Article "Brains of Britain" 8-14 Feb 08 (Presentation)
Company Statement:
The Amphion management team has been working together for over twenty years. We have been directly involved in the start-up and development of more than thirty-five companies in the medical and information technology sectors. As anyone who has done this can testify, starting and building technology intensive companies takes commitment and experience, patience and persistence and above all, a systematic approach.
The Amphion model is designed to embrace one new company per year. It starts with a rigorous selection process. We choose carefully because we know that once we adopt a new Partner Company, we plan to see it through to success. We are not just investors but builders and partners with the inventors, founders, and management teams we support. Before we commit to a new Partner Company, we immerse ourselves over many months in the technology and the markets it will address, digging into key aspects of the business proposition. We need to be happy with the strength of the intellectual property, the financing profile and the people and we need to be sure we are working with a technology that has demonstrated “proof of concept”. We don’t want to speculate on a technology, however exciting, that may or may not work. We want to be sure that our role is to help the company develop and market a product that will address existing market segments and become a good business.
The pace of technical innovation in medicine and IT shows no signs of slackening. The convergence of scientific disciplines is throwing up more opportunities for important products, many of which will change or save lives and some of which have the potential to be commercially successful if supported in the right way. The Amphion team’s skill is to select these opportunities and support them through the process of achieving their objectives.
Current Operations:
Overview
Current Portfolio Summary (as of 31 December 2009)
Partner Companies
Joint Ventures
| Company | Amphion Holding |
Company Description |
Valuation |
100% |
Intellectual Property Development
|
N/A* |
|
50% |
Middle East Joint Venture |
$ 6 Million |
* As DataTern is 100% owned by Amphion, it is consolidated into Amphion’s financial statements.
Management
Richard M. Mansell-Jones, Non-executive Chairman
Robert J. Bertoldi, President, Chief Financial Officer, and Executive Director
Anthony W. Henfrey, Non-executive Director
R. James Macaleer, Non-executive Director
Richard C. E. Morgan, CEO and Executive Director
Gerard M. Moufflet, Non-executive Director
Katharine B. Cushing, Strategic Investment Advisor
Major Shareholders
No info available.
Contact Information
Amphion Innovations US, Inc.
330 Madison Avenue
New York, NY 10017
USA
Phone (212) 210 6282
Fax (212) 210 6271
Email info@amphionplc.com
Web www.amphionplc.com
Amphion Innovations UK, Ltd.
10 Greycoat Place
Westminster
London SW1P 1SB
UK
Phone (44) 020.7016.8821
Fax (44) 020.7016.9100
Email info@amphionplc.com
Web www.amphionplc.com
Corporate Information
Nominated Advisor to the Company
Charles Stanley Securities
25 Luke Street
London EC2A 4AR
Broker to the Company
Charles Stanley Securities
25 Luke Street
London EC2A 4AR
Advisors to the Company as to English Law
Richards Butler
Beaufort House
15 St. Botolph Street
London EC3A 7EE
Advisors to the Company as to Isle of Man Law
Cains Advocates Limited
15-19 Athol Street
Douglas, Isle of Man IM1 1LB
Registrars
Neville Registrars Ltd.
Neville House
18 Laurel Lane
Halesowen
West Midlands B63 3DA
Public Relations
Cardew Group
Financial & Corporate Communications
12 Suffolk Street
London SW1Y 4HG
Investors interested in Amphion Innovations recently viewed:
- Access Pharmaceuticals (OTCBB: ACCP)
- Alliance Pharma (AIM: APH)
- Asterand (LSE: ATD)
- Biocompatibles (LSE: BII)
- BioNeutral Group (OTCBB: BONU)
- Bionomics (ASX: BNO)
- Circadian Technologies Limited (ASX: CIR)
- CogState (ASX: CGS)
- e-Therapeutics plc (AIM: ETX)
- Eco Animal Health Group Plc (AIM: EAH)
- Epistem (AIM: EHP)
- ImmuPharma PLC (AIM: IMM)
- Lipoxen (AIM: LPX)
- Medical Australia Limited (ASX: MLA)
- Oxford Nutrascience (AIM: ONG)
- Renovo Group Plc (LSE: RNVO)
- Rexahn Pharmaceuticals (AMEX: RNN)
- Silence Therapeutics (AIM: SLN)
- Starpharma (ASX: SPL)
- Stirling Products Limited (ASX: STI)








